Has Edward McPherson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,213,286 in general payments to Edward McPherson, MD across 291 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Edward McPherson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Edward McPherson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Edward McPherson, MD

Orthopaedic Surgery · Los Angeles, CANPI 1659360576

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $852,960 of the $1,213,286 with a category attached, or 70.3%. Zimmer Biomet accounts for 69.2% of it on its own, with 8 other manufacturers making up the rest. Among orthopaedic surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,213,286in general payments, 2019–2025

Across 291 payments — averaging $4169.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Zimmer Biomet$839K
Austin Medical Ventures Inc$284K
Biocomposites Inc$40K
Bone Support Inc.$26K
Heraeus Medical, LLC.$23K
Si-bone, Inc.$372
plus $173 from 3 others

$104,022in research payments, 2019–2025

Across 4 payments — averaging $26,006 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Bone Support Inc.$104K

What the payments were for

Royalty or licence$852,96070%
Consulting fees$239,40520%
Speaking & faculty fees$25,4002%
Travel & lodging$36,5903%
Food & beverage$5,4730%
Education$53,4584%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Zimmer Biomet	249	$839,373
Austin Medical Ventures Inc	23	$284,439
Biocomposites Inc	3	$40,173
Bone Support Inc.	7	$25,501
Heraeus Medical, LLC.	2	$23,254
Si-bone, Inc.	4	$372
Smith+Nephew	1	$122
Innovation Technologies Inc	1	$37
Johnson & Johnson	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Arcos$630,870
Synthecure$224,614
Synthecure Calcium Sulfate$65,651
Stimulan$40,173
Persona$37,281
CERAMENTBONE VOID FILLER$25,479
Arcos Revision Hip Instrumentation$23,036
G7$17,627
OSS Orthopedic Salvage System$12,750
OSS-Knees$9,775
NCB Instruments/Plates/Screws$9,448
PD-Hip-New Product$8,114
Vanguard 360$7,200
TM Femoral Cones$7,200
LCCK NexGen$7,200
OSS$7,200
Vanguard$4,800
Synovasure Alpha Defensin$3,155
ABSORB$2,400
Hips Product Portfolio$1,625

How this compares

$1,213,286 in reported general payments places this provider in the 95th percentile of 1,808 orthopaedic surgery providers in California.

See all orthopaedic surgery providers in California →

Medicare billing

Part B allowed, 2024

$395,546

Medicare patients

289

Services billed

2,847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Celecoxib	69	$5,944
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	35	$932
Doxycycline Hyclate	11	$893
Oxycodone Hcl	13	$200
Spironolactone	12	$62
Amoxicillin	24	$20

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Los Angeles

Kelly VinceLos Angeles$9.6M
Jay LiebermanLos Angeles$4.8M
Thomas SchmalzriedLos Angeles$4M
David SkaggsLos Angeles$2.6M
David ThordarsonLos Angeles$2.5M
Daniel AllisonLos Angeles$1.1M
Justin SalimanLos Angeles$912K
Charles MoonLos Angeles$760K
Andrew SpitzerLos Angeles$738K
Yashar JavidanLos Angeles$685K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →